Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3–4)-sensitive hepatocardiorenal syndrome-Reference-Cited by-同舟云学术

Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3–4)-sensitive hepatocardiorenal syndrome

Published:2022-06 Issue: Volume:14 Page:100176
ISSN:2589-9368
Container-title:Metabolism Open
language:en
Short-container-title:Metabolism Open

Author:

Crisóstomo Thuany,Pardal Marco A.E.,Herdy Simone A.,Muzi-Filho Humberto,Mello Debora B.,Takiya Christina M.,Luzes Rafael,Vieyra Adalberto^ORCID

Funder

FAPERJ

CAPES

CNPq

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Angiotensin-(3–4) normalizes blood pressure, decreases Na+ and energy intake, but preserves urinary Na+ excretion in overweight hypertensive rats;Luzes;Biochim Biophys Acta (BBA) - Mol Basis Dis,2021

2. How western diet and lifestyle drive the pandemic of obesity and civilization diseases;Kopp;Diabetes Metab Syndr Obes,2019

3. Is angiotensin-(3–4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system?;Dias;J Renin-Angiotensin-Aldosterone Syst JRAAS,2017

4. Angiotensin-(3–4) counteracts the Angiotensin II inhibitory action on renal Ca2+-ATPase through a cAMP/PKA pathway;Axelband;Regul Pept,2012

5. Cardio-renal syndromes: a systematic approach for consensus definition and classification;Ronco;Heart Fail Rev,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Ultrasound Characterization of the Diet-Induced Obesity (DIO) Model in Young Adult c57bl/6j Mice: Assessment of Cardiovascular, Renal and Hepatic Changes;Journal of Imaging;2024-09-04

2. Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?;Frontiers in Pharmacology;2024-04-10

3. Reactive oxygen species impair Na+ transport and renal components of the renin-angiotensin-aldosterone system after paraquat poisoning;Anais da Academia Brasileira de Ciências;2024

4. Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances;Metabolism Open;2023-03